



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/003,400	10/22/2001	Neal D. Epstein	4239-61090	5338

7590 05/05/2003  
KLARQUIST SPARKMAN, LLP  
One World Trade Center  
Suite 1600  
Portland, OR 97204

EXAMINER

LI, QIAN J

ART UNIT	PAPER NUMBER
----------	--------------

1632

DATE MAILED: 05/05/2003

S

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

10/003,400

Applicant(s)

EPSTEIN ET AL.

Examiner

Q. Janice Li

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 22 October 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-50 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-50 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

**DETAILED ACTION**

***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S. C. 121:

- I. Claims 1-12, 25, 43, 49, and 50 are drawn to an isolated mammalian c-kit/c-met cardiomyocyte precursor cell, and a pharmaceutical composition or kit comprising the cell. Classified in Class 435, subclass 325.
- II. Claims 13-24, and 26-34 are drawn to a method of isolating a c-kit/c-met cardiomyocyte precursor cell of muscular origin, and a method of differentiation said precursor cell. Classified in Class 800, subclass 13.
- III. Claim 35 is drawn to differentiated mammalian c-kit/c-met cardiomyocytes. Classified in Class 435, subclass 325.
- IV. Claims 36-40 are drawn to a method of treating a myocardial injury in a subject using c-kit/c-met cardiomyocyte precursor cells. Classified in Class 424, subclass 93.2.
- V. Claims 41-42 are drawn to a method of treating a myocardial injury in a subject using differentiated beating cardiomyocytes. Classified in Class 424, subclass 93.2.
- VI. Claims 44-48 are drawn to a method for screening for an agent using a c-kit/c-met cardiomyocyte precursor cell. Classified in Class 435, subclass 4.

2. The inventions are distinct, each from the other because of the following reasons.

Inventions III and I are independent or distinct inventions. Inventions are distinct if it can be shown that they are not disclosed as capable of use together and they have different modes of

Art Unit: 1632

operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, each of the groups III and I are drawn to a different product, i.e. a precursor cell of cardiomyocytes or a differentiated cardiomyocyte. The different products are distinct in morphological structure and biological function, as well as modes of operation when used as therapeutic and screening agents, and they belong to different biological entities. For example, the terminally differentiated cardiomyocytes have limited proliferative ability but the characteristics of spontaneous beating whereas the precursor cells could further differentiate.

Inventions IV-VI, and II are independent or distinct inventions. Inventions are distinct if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, groups IV-VI, and II are drawn to different methods for isolation, and using the cells. Each of the groups differs in starting materials used (precursor cells or cardiomyocytes), the method steps (in vivo vs. ex vivo), and the mode of operation, and thus, require distinct technical considerations and search criteria.

Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the cells could be made by a materially different process, such as differentiating from an embryonic stem cell.

Inventions IV, VI, and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the

product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product of group I could be used in preparing a pharmaceutical composition for treating a subject as claimed in group IV, or could be used in a screening process as claimed in group VI. The process of group IV could be practiced with another materially different product, such as a differentiated cardiomyocyte.

Inventions V and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process of treating myocardial injury could be practiced with a stem cell, for example; and the cardiomyocyte could be used in a different process, such as screening for a cardiomyocyte-specific drug.

The differences of the Inventions I-VI are further underscored by their divergent classification and independent search criteria.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and different search criteria, it would impose an undue burden to the Office if all the groups are examined together, thus, restriction for examination purposes as indicated is proper.

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is advised that where a single claim encompasses more than one invention as defined above, upon election of an invention for examination, said claim will only be examined to the extent that it reads upon the elected invention.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Q. Janice Li whose telephone number is 703-308-7942. The examiner can normally be reached on 8:30 am - 5 p.m., Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah J. Reynolds can be reached on 703-305-4051. The fax numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of formal matters can be directed to the patent analyst, Dianiece Jacobs, whose telephone number is (703) 305-3388.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235. The faxing of

Application/Control Number: 10/003,400

Page 6

Art Unit: 1632

such papers must conform to the notice published in the Official Gazette 1096 OG 30  
(November 15, 1989).

A handwritten signature in black ink, appearing to read 'Q. Janice Li', with a stylized flourish at the end.

Q. Janice Li  
Examiner  
Art Unit 1632

QJL  
May 1, 2003